0ECD AssocCompanies2017 - green

YOUR BIOSCIENCE COMPANY DESTINATION

Associate Company
Directory

YOUR BIOSCIENCE COMPANY DESTINATION

grow with us

Next door to discovery - with space, talent and bandwidth to grow
Locating on HudsonAlpha’s campus offers life sciences companies of any stage or size access
to the cutting edge of biotechnology and flexibility to grow. Superior shared amenities and
administrative support power your progress and provide space for expansion.

Culture of Collaboration
Acquisition, analysis and application of genomic research inspires innovations in our
life sciences companies. HudsonAlpha offers turnkey or build-to-suit office/lab space in an
energizing environment that blends research, education, medicine and commercialization.

Unrivaled Inspiration and Business Advantages
• campus address with shared spaces and centralized services including
• labs built to NIH standards for biosafety and emergency power
• strategic business and investment support
• fully-managed, on-site IT services with multiple, diverse path ISP up to 200G

22

FROM DISCOVERY TO ENTERPRISE

HudsonAlpha Institute for Biotechnology translates the promise of genomics into
measurable, real-world benefits for people around the globe.

HudsonAlpha’s innovation contains four synergistic missions:
! research-driven discovery
@ education
# genomic medicine
$ economic development

Under the leadership of Richard M. Myers, PhD, HudsonAlpha connects these four
endeavors into a single enterprise, making it one of the most unique locations for
genomic discovery in the country. HudsonAlpha generates major discoveries that impact
disease diagnosis and treatment, creates intellectual property, fosters life sciences
companies and expands the number of biosciences-literate people, many of whom
will take their place among the future life sciences workforce.

11% HudsonAlpha was founded on the coattails of the
of the Human Human Genome Project which used DNA that
Genome Project was synthesized in the labs of Jim Hudson’s first
company, Research Genetics. Dr. Myers used the
DNA from Hudson’s company to sequence 11% of
the Human Genome Project, an unprecedented
“Team Science” approach to the science world.

The primary benefit of establishing a startup, fostering growth of an early
stage company, or relocating a mature enterprise to HudsonAlpha is
collaboration with leading-edge intellectual talent, that provides
opportunities for life sciences companies to grow and expand.

3

2016

Associate Companies

Alimetrix ..................................... 25 Kymanox ..................................... 25
Ariel Precision Medicine ............... 5 Leavendary................................... 17
BioDynami ..................................... 6 Microarrays, Inc. ......................... 18
Celsion-Egen ................................ 7 Mira Pharmaceuticals ................ 25
CFDRC ........................................... 8 Molecular Logic .......................... 25
Concero Scientific, Inc. ............... 25 MVW Nutritionals ........................ 19
Conversant Bio .............................. 9 Prozone Water Products, Inc. .... 20
Diatherix Laboratories, Inc. ........ 10 Serina Therapeutics, Inc. ............ 21
Envision Genomics ..................... 25 The Smith Family Clinic ............. 26
Foresight Biosciences, Inc. ......... 11 Sulfilatec, Inc. ............................. 26
GeneCapture ............................... 12 Synvivo, LLC ................................ 26
iCubate, Inc. ................................ 13 Thermo Fisher Scientific, Inc. ... 26
iRepertoire, Inc............................ 14 transOMIC Technologies ............. 22
iXpress Genes ............................. 15 Trideum Biosciences .................. 23
Jackson Center ........................... 25 Ubiquity Genomics ...................... 26
Kailos Genetics, Inc..................... 16 Volatile Analysis Corporation ..... 24

For more information about Associate Companies, contact
Ross Ivey | [email protected] | 256.327.9480

4

www.arielmedicine.com ARIEL is an advanced diagnostics laboratory and bioinformatics
services company providing genomics-based tests that aid in
256.327.9569 the diagnosis, monitoring and treatment of Complex Chronic
Disease and Disorders. Our mechanistic diagnostic process
Leadership approach is intended to enable informed intervention prior to
Mary Del Brady, M.B.A the development of end-stage outcomes.
We believe that ARIEL’s technologies can lead a paradigm
Chief Executive Officer shift from single gene (Mendelian) genetics to multifaceted,
complicated gene to gene interactions that interface
Jessica M. Gibson, M.B.A. with familial and environmental factors to provide a more
comprehensive view of disease trajectory and precise
Executive Vice President and Chief Scientific Officer therapeutic options. Our SMART-MD platform integrates
the patient’s symptoms and genetics (derived through Next
Nicholas Borys, M.D. Generation Sequencing of more than 700 gene targets)
with complex medical information that includes systems
Chief Commercial Officer modeling, machine learning and other advanced reporting
technology. The process tests one patient and his or her
John “Tory” Moore, CFA disease behavior against databases of well-mapped,
complex disease patterns to help determine both the
Chief Financial Officer underlying causes of the disease and the optimal treatment plan.
While headquartered in Pittsburgh, PA, ARIEL has an
Jessica LaRusch, Ph.D. office within the Hudson/Alpha Institute for Biotechnology,
a 152 acre campus located in Huntsville, Alabama that is
Lead Genetic Scientist shared by some of the world’s “genomics thought leaders”,
forward-thinking entrepreneurs and inventive educators.
Chris Hvziak We are leveraging their state-of-the-art Genomic Services
Laboratory to develop and validate each of our tests prior to
Senior Systems Administrator commercialization. The HudsonAlpha laboratories provide
access to the most advanced scientific tools available in the field.

5

www.biodynami.com BioDynami Corporation is a biotechnology company that provides
innovative solutions for life sciences research and development.
256.872.0805 Currently, BioDynami is focusing on next generation sequencing
(NGS) and molecular cloning. We provide reagents for NGS, DNA
Leadership cloning, and PCR cloning. We also offer services for NGS library
Lisa Chen, M.B.A construction, custom vector design, and DNA cloning. Our goal
is to provide the best solutions in the field to make Research and
Chief Executive Officer Development life easier.

Jun Song, M.D., Ph.D. Next Generation Sequencing
•Quick and efficient DNA library prep reagents for
CTO
diverse needs
•Library quantification reagents
•NGS services

Molecular Cloning
•Effective and simple cloning kits for any type of DNA

fragments
•Cloning vectors for common DNA cloning and large

DNA cloning
•Cloning services

DNA Ladders
•Ready-to-load DNA ladders: cover from 20 bp to 20 kb

with easy identification band

Services
•Next Generation Sequencing: DNA library prep,

sequencing
•Cloning: any type of DNA fragment cloning; vector

design and construction

6

Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA - or DNA-
based therapies. The Company’s lead program is ThermoDox®,
a propretary heat-activated liposomal encapsulation of
doxorubicin, currently in Phase III development for the treatment
of primary liver cancer and Phase II development for recurrent
chest wall breast cancer. The pipeline also includes GEN-
1, a DNA-based immunotherapy for the localized treatment
of ovarian and brain cancers. Celsion has two platform
technologies for development of novel nucleic, acid-based
immunotherapies and other anti-cancer DNA or RNA therapies,
including TheraPlus™ and TheraSilence™.

www.celsion.com Technology

609.896.9100 ThermoDox® is Celsion’s lead product candidate which
incorporates lysolipid thermally sensitive liposomes
Leadership (LTSLs), a unique liposomal technology that allows
Michael H. Tardugno for the triggered release of a drug payload through
low temperature (just above body temperature) heat
Chairman, President and CEO activation.

Khursheed Anwer, Ph.D., M.B.A. TheraPlas™ is a versatile technology platform for the
delivery of DNA and messenger RNA (mRNA) therapeutic
Executive Vice President and Chief Scientific Officer via synthetic non-viral carriers and is uniquely capable of
providing cell transfection capability for double-stranded
Nicholas Borys, M.D. DNA plasmids and large therapeutic RNA segments such as
mRNA.
Senior Vice President and Chief Medical Officer
TheraSilence™ is a versatile technology platform focused
Jeffrey W. Church on delivering synthetically generated small inhibitory RNAs
(siRNAs), microRNAs, microRNA mimics, and related
Senior Vice President and Chief Financial Officer molecules that can regulate protein expression by exploiting
endogenous cell mechanisms.
Jason Fewell, Ph.D.
Product Pipeline
Vice President, Preclinical Research
Celsion’s pipeline includes two clinical-stage candidates
targeting various oncology indications and two platform
technologies for the development of novel nucleic acid-based
immunotherapies and other anti-cancer DNA/RNA therapies.
These include:

ThermoDox® is a proprietary heat-activated liposomal
encapsulation of doxorubicin. Celsion is currently enrolling
a 550 patient. Phase III pivotal study of ThermoDox® in
combination with radiofrequency ablation in primary liver
cancer. ThermoDox® is also being evaluated in two Phase
II studies in recurrent chest wall breast cancer in the U.S.
and Europe.

GEN-1 for Ovarian and Brain Cancers - Positive safety

and encouraging Phase I results with GEN-1 given as

monotherapy in patients with peritoneally metastasized

ovarian cancer. A Phase Ib trial of GEN-1 in combination with

PEGylated doxorubicin in patient with platinum-resistant

ovarian cancer has completed enrollment. The Company

plans to initiate additional clinical studies with GEN-1 as

part of a first line treatment for ovarian cancer as well as a

combination treatment for platinum resistant ovarian cancer.

GEN-1 has also demonstrated encouraging preclinical
7
activity in glioblastoma multiforme (brain cancer).

www.cfdrc.com CFDRC’s mission is to develop and commercialize innovative
technologies. Most of the company’s work is performed
256.726.4800 through highly competitive research contracts from
[email protected] government agencies. Three core focus areas are aerospace
and defense, biomedical and life sciences, and energy and
Leadership materials.
Sameer Singhal
Bio and Energy Technologies
VP and Chief Operating Officer
The CFDRC Bio & Energy Division has a patent portfolio
Kapil Pant, Ph.D. consisting of ~25 patents in the following key areas:

VP of Biomedical and Energy Technologies • Microfluidics – miniaturized sample preparation and
manipulation including cell-based assays; leading
8 product technology is SynVivo.

• Electrochemical Devices – Variety of power sources
including biologically inspired prototypes; leading
product technology is Bio-Battery.

• Chem/Bio Sensors – Optical and electrical sensors for
detection of chemical and biological agents.

• Advanced Software Tools – Custom software tools for
design analysis of material, devices, and systems.

Products

• SynVivo – Realistic, dynamic, cell-based assays
enabling accurate studies of cellular behavior, drug
delivery and accelerating drug development cycles.

• Bio-Battery – Biologically inspired power sources
utilizing enzymes as catalysts to convert readily
available fuels such as sugar and alcohol directly into
electrical energy.

Testing

CFDRC’s SynVivo product is currently being tested by a
number of academic collaborators, small biotechs and
pharma.

CFDRC’s Bio-Battery product is receiving application
development funding from a defense contractor and is
scheduled to undergo field trials in 2014.

www.conversantbio.com Conversant Bio provides biospecimens and ancillary
services to researchers focused on oncology, hematology, and
256.327.0655 immunology research.
[email protected]
Conversant Bio provides primary tissues and cells matched
Because patients are waiting...™ with the clinical information scientists need to better validate
their research so new drugs can reach the patient bedside
Leadership more quickly. Most projects are prospective in nature;
Marshall Schreeder, Jr. Conversant Bio collects and processes specimens that meet
each researcher’s specific criteria for patient selection and
Chief Executive Officer, Co-Founder sample preparation. Additionally, Conversant Bio continues
to expand its ability to source normal biospecimens to
Luke Doiron support general immunology research.

Chief Commercial Officer, Co-Founder Trials/Testing

Jay Scherer Conversant Bio is currently involved in more than 200 active
preclinical or clinical studies with scientists in the U.S., Europe
Chief Operating Officer and Asia. Examples of past research include:

Will Taylor Non-small cell lung cancer
Longitudinal collection of blood, sputum and tumor tissue
Chief Financial 0fficer helped develop companion diagnostic for EGFR targeted
therapy in Phase I trials. Proved that diagnostic assay is
possible on less invasive specimens (blood/sputum).

Glioblastoma multiforme, hepatocellular carcinoma,
breast cancer (triple negative), colorectal cancer

Collection of blood and tumor tissue to identify additional
disease indications for lung cancer drug in a Phase III trial.

Breast cancer, renal cell carcinoma
Collection of tissue and treatment outcome information
to validate prognostic test that identifies Herceptin and
Sutent responders/non-responders for breast cancer
and renal cell carcinoma, respectively.

Asthma
Collection of blood samples to test primary immune cells
in vitro in order to better understand the mechanisms of
steroid resistance and the potential of targeted therapies
to restore steroid responsiveness.

Mesothelioma
Collection of blood and tumor tissue to validate PI3
kinase biomarker for novel therapeutic compound.
Results were extremely promising and researcher plans
to push drug from Phase I to Phase III trial because of
unmet medical need.

9

ON TARGET, ON TIME DIAGNOSTICS

Diatherix is an innovative, CLIA certi ed, molecular TEM-PCR Bene ts:
diagnostic laboratory utilizing proprietary TEM-PCR™
(Target Enriched Multiplex Polymerase Chain Reaction) TEM-PCR technology is a unique, multiplex
technology for precise detection of infectious diseases ampli cation platform designed to overcome the
– linking diagnostics to therapeutics. challenges that exist with conventional laboratory
methods and real-time PCR applications.
Diatherix Distinctions:
Improved speed and accuracy of laboratory results
• Simultaneousidenti cationofbacteria, viruses, lead to:
parasites, Candida and antibiotic resistance
• Improved patient outcomes
• Detectionofbacteriainthepresenceofantibiotics • Cost reduction and avoidance
• Increasedsensitivityandspeci city • Reduced antibiotic utilization
• Simplicityofsinglesamplecollection • Increased patient satisfaction
• Onedayresults* • Greater clinical value

Linking Diagnostics to Therapeutics™ * Determined by sample receipt.

866.979.4242 / www.diatherix.com

© 2013 Diatherix Laboratories, Inc. All rights reserved.

10

www.foresight-bio.com Foresight Biosciences commercializes technology for
glycobiology research with an emphasis on creating tools for
256.327.9404 engineering glycoconjugates that alter the biodistribution of
[email protected] administered therapeutics.

Technology

Most FDA approved protein therapeutics are glycosylated.
Natural protein glycoconjugates have very specific
structures that affect their function and distribution.
Therapeutic proteins derived from nonhuman cells often
exhibit improper glycosylation that require modification prior
to administration.

The company’s technology facilitates protein posttranslational
modification, glycoconjugation, and glycan analysis.

Product/Service

The company offers benchtop assays for glycoprotein
terminal fingerprint analysis, recombinant enzymes, and
convenient kits for identifying, repairing and modifying
protein glycosylation.

Leadership
Ronny Hughes, Ph.D.

President

Ernest Curto, Ph.D.

Senior Scientist

11

www.genecapture.com 1 hour Infection Detection

256.783.4506 GeneCapture, a startup medical device company is
[email protected] prototyping a portable instrument to rapidly screen for
multiple pathogens causing human disease. The company
developed a novel, now patented protocol named CAPTURE™
(Confirm Active Pathogens Through Unamplified RNA
Expression). This technique allows faster, inexpensive
options for infection detection. Validation tests are underway
on human, plant and animal pathogens.

Leadership
Peggy Sammon

Chief Executive Officer

Krishnan Chittur, Ph.D.

Chief Technology Officer, Founder

12

www.icubate.com iCubate® is a privately held molecular diagnostic company with
groundbreaking technology and an innovative platform to detect
256.603.7042 infectious diseases. The company is currently developing tests
[email protected] for companies and organizations both in the U.S. and overseas.

Leadership Technology
Jian Han, M.D., Ph.D.
Founder, Jian Han, M.D., Ph.D., developed patent-protected
Founder, Chairman of the Board arm PCR reaction that addresses up to 30 genes in one
test used by iCubate. The research and potential clinical
Carter Wells possibilities are endless in designing tests to differentiate
between organisms and drug resistance markers.
Chief Executive Officer
Products

The iCubate System (iC-System) performs extraction,
amplification and detection using the patented iC-Cassette.
The iC-Cassette is preloaded with our arm-PCR reagents with
the ability to detect multiple organisms or gene markers in one
test. The iC-Cassette is a closed system, ensuring a low rick
of contamination and false positive results. The iC-Processor
processes up to four iC-Cassettes at one time, with multiple
iC-Processors linked together for higher throughput. After
processing, the iC Cassette is scanned using the iC-Reader with
results appearing in an easy to understand report through the
company’s proprietary iC-Report.

Clinical Application: iCubate® completed Beta
testing in 2014 and is working toward FDA approval
with the iC-GPC or bloodstream infection panel. This
test is used for blood culture bottles to detect multiple
pathogenic targets and antibiotic resistance markers
to further aid physicians with diagnosis. Other tests
are currently under development. Potential customers
include hospitals, physicians’ offices, research and
reference labs.

iCubate 2.0: The iC System is being marketed and
sold in the research-use market. Customers include
U.S. government agencies and universities along with
government agencies and organizations in Asia. The
iC-System can be customized for specific customers to
detect a variety of organisms.

Trials/Testing

Data generated during Beta studies performed at three
major reference laboratories throughout the United States
verified strong product performance. iCubate® completed
its blood stream infections Beta testing in 2014 with greater
than 98.6% agreement across all targets and greater than
98.8% specifically for all targets and is currently performing
clinical studies with the company’s first product for clinical
diagnostic use. iCubate® is moving forward on a regulatory
path anticipating obtaining FDA clearance in 2015.

13

www.irepertoire.com An immune repertoire is the sum total of all the functionally diverse
B and T cells in an individual’s circulation at any given moment.
256.327.0948 Each person has an individualized immune repertoire.
[email protected]
iRepertoire uses immune repertoire sequencing technology to
Leadership access the body’s immunological memory, or “logbook” of all past
Jian Han, M.D., Ph.D. infection and disease. Sequencing the immune repertoire can yield
insights into the nature of the body’s immune response to disease
Chief Executive Officer and infection. The future market for iRepertoire will be in clinical
and research applications that require immune assessment such
14 as drug treatment monitoring, immune monitoring after stem cell
transplantation, vaccine studies, and biomarker development.

iRepertoire sells reagent kits and services for immune repertoire
amplification of B cell and T cell receptor sequences, which are
compatible with downstream Next Generation Sequencing (NGS).
iRepertoire has also automated immune repertoire amplification and
extraction on their sister company’s iC-processor (iCubate, Inc.).

Technology

iRepertoire’s novel arm-PCR (amplicon rescued multiplex PCR) is
very sensitive, allowing the amplification of an inclusive immune
repertoire from a small sample.

Product/Service

The company provides primer kits and amplification to sequencing
services to examine the TCR and BCR immune diversity in both
humans and mice. iRepertoire also offers access to its proprietary
repertoire analysis tools with the purchase of its reagent systems.

iRepertoire’s reagent systems allow researchers to easily and
inexpensively generate their own high-throughput sequencing
libraries in the convenience of their laboratory and analyze their
data with the iRepertoire’s proprietary software pipeline at no
additional cost.

Testing

iRepertoire is proud to be a part of the nonprofit initiative
R10K, or Repertoire 10,000, with the HudsonAlpha Institute for
Biotechnology, which aims to study the immune repertoire of 100
different diseases. The company has developed two key indices to
describe the immune repertoire, i.e., the diversity index and the
sharing index. These indices allow iRepertoire to identify disease
specific signatures for diagnosis, prognosis and treatment
guidance.

www.ixpressgenes.com iXpressGenes is a bioengineering and synthetic biology
company focused on Protein Crystallization Services,
256.426.0413 Instrumentation and Contract Research.
[email protected]
Products/Services

Instrumentation - The CrystalX2 Automated Imager is a
novel optical scanner designed to identify protein crystals at
a very early stage using tracefluorescence. It is designed for
use in research, biotechand pharma labs, and is considered
a best practice protocol.

Protein Services – iXG provides contract services and
products for proteins and enzymes, from purification to
verification and engineering. The company has exclusive
access to microbes from the Atlantic Mid Ridge Rainbow
Deep Sea Vents. These microbes have led to engineered
enzymes with special traits, including faster reactions in
PCR and providing more temperature stable polymerases.

Research – Scientists at iXG are exploring synthetic biology
solutions in the areas of healthcare, environment and defense.
Current research is being conducted on PTSD biomarkers
and microgravity grown crystals on the International Space
Station.

Leadership
Joseph Ng, Ph.D.

Chief Executive Officer

15

www.kailosgenetics.com With a focus in the fast-growing world of next generation
sequencing, Kailos Genetics, through its CLIA Ser-vices
256.327.9800 Laboratory, analyzes DNA for “genetic clues” associated
with drug response, adverse response and diagnosis of
Leadership disease. These clues enable physicians to proactively identify
Brian Pollock responders and non-responders to certain drug therapies,
avoid serious adverse drug reactions that are genetically
President and Chief Executive Officer linked, and diagnose inherited and non-inherited diseases.

D. Troy Moore The CLIA Services Laboratory at Kailos Genetics currently
provides drug metabolism/pharmacogenomic testing services
Chief Scientific Officer for (1) drugs and conditions commonly associated with cardiac
disease, (2) for drug and conditions common associated with
Randy C. Bachmeyer mental health issues, and (3) for drugs commonly used to
treat pain and pain syndromes. The lab also provides cystic
Chief Technology Officer fibrosis screening (CFTR gene). Other undisclosed tests are
undergoing clinical validation.

Kailos Genetics services all physician specialties and
has business-to-business relationships to leverage its
TargetRich™ technology in non-physician and research
markets.

Key Technology

Kailos Genetics is setting new expectations in targeted
enrichment with its proprietary technology – TargetRich™.
TargetRich™ achieves its high content definition and
specificity through two discrete targeting steps and employs
a clean-up step to remove any off-target product prior to
next generation sequencing. This enables TargetRich™ to
efficiently use sequencer capacity, providing a cost effective
method to detect genetic changes known to be associated
with both disease detection and selection of the most
appropriate drug therapy.

16

Propagating Legendary Yeast Leavendary provides craft brewers customized “big-
brewery” biology that fits the craft brewing context.
www.leavendary.com Innovative craft brewers continually produce new recipes
that create new and responsive biology requirements
256.513.6258 for Leavendary. Leavendary ensures brewers have
“pitch perfect” yeast, a first-class quality program, and
[email protected] the biology expertise they need to succeed in a highly
competitive market.
@leavendary
Yeast
• Delivering pitchable quantities
• Banking services
• Strain selection assistance

Microbiology
• Full service testing
• Contaminant ID/remediation
• Draught testing

Bio R&D
• Custom yeast strains
• Consulting services
• Wild yeast “domestication”

Leadership Perfect Pitches, Every Time
Peyton McNully Craft Biologists
Serving Craft Brewers
Founder Full Service Beer Biology

17

www.microarrays.com Microarrays Inc. is a technology company that uses precision
robotics to manufacture a product called a microarray.
256.327.0544 Microarrays are orderly arrangements of capture probes
[email protected] usually made of DNA and/or proteins. These probes are able
to “capture” biological information, allowing researchers
to rapidly sort through complex samples and identify the
presence or absence of targets of interest.

Within healthcare, everyone from the patient to the providing
institution benefits from the use of array-based tools. For the
patient, the diagnostic time savings can mean the difference
between a positive or negative outcome, especially in regard
to infectious diseases.

Technologies

The technologies developed at MI span the full spectrum
of array production, from early project conception to
manufacturing, final quality control and product validation.
MI develops all of the motion-control software, printing
robotics and microfluidic deposition technologies used by MI
to provide high throughput capability to any project.

Product/Services

DNA/protein/antibody arrays - Array-based tools allow
scientists to better understand the fundamental aspects of
cellular biology, as well as to explore the underlying aspects
of human genetic disease. MI provides full custom service
for organizations seeking assay development assistance.

While best known in the industry for microarray production
and assay development, MI has expanded to include gene
expression laboratory services.

Leadership
Joel Peek, Ph.D.

President and Chief Executive Officer

18

www.mvwnutritionals.com MVW Nutritionals is a privately held company, with the mission
www.cfmultivitamins.com
of providing leading edge nutritional supplements and vitamins
855.236.8584 for persons who have cystic fibrosis and other gastrointestinal
[email protected] disorders. Our goal is to deliver exceptional product profiles, coupled
with outstanding service. We believe that quality in what we do, at
a reasonable price, are important, and we are committed to this
mission.

About the Company

The Company is pleased to offer multivitamin products developed to
address the varying needs of individuals who have CF. Please see
the table below. In 2014, MVW Nutritionals introduced the first mul-
tivitamin product to address the CF Foundation’s Guidelines for “step
increases” in vitamin D, and will introduce addition products and ser-
vices in 2015 to support the management of serum vitamin D levels.
The Company is also in the process of expanding it’s focus in 2015 to
support the nutritional aspects of other gastrointestinal disorders.

Products and Availability

Our products are manufactured at certified cGMP facilities to meet
the guidelines set out by the FDA. Routine testing occurs and every
product receives a Certificate of Analysis (“COA”) upon release by the
Quality Assurance team. In addition to making sure that each product
meets its label claim when released, products also undergo stabil-
ity testing to provide the confidence that the levels of vitamins and
minerals needed in your care are consistent with the label through
product expiration. We believe this is important, as we seek to ensure
the highest standard of quality control from our manufactures for
our customers.

MVW’s supplements and vitamins support the Wholesaler Reference List for MVW Multivitamin Supplement Products
cystic fibrosis community and others with gastro-
intestinal disorders. Qty Product McKesson Cardinal ABC Item # Morris & UPC
Prescribed Economost# CIN Dickson
Leadership
Mike Walters Softgesl 2718096 4988804 10140549 044F4401 858204004009

President 60 CT

60 CT bubblegum flavor 5045976 044F4301 858204004085

60 CT orange flavor 2718906 4988796 10140548 044F4901 858204004016
2905867
Pediatric Drops 2905859 5002902 044F4601 858204004047

30 ML 044F4501 858204004061

SoftgelsD3000

60 CT

Retail Pharmacy
Locations

Melanie Vandiver Outside the U.S. MVW Nutritionals supports the CF Community in
Canada through Health Canada’s Special Assistance Program;
Operations and is working with others on product registration in several countries.

Suzanne Michel

Registered Dietician

19

Healthier Water. Pure and Simple. Prozone Water Products Inc, founded by physicist Ron Barnes in 1977, pro-
vides unique solutions and leading edge Ozone, Germicidal UV-C, and Ad-
www.prozoneint.com vanced Oxidation Process technologies relating to purification processes of
fluids, air and surfaces. As a recognized industry leader, Prozone’s Hybrid
256.539.4570 Cold Plasma and AOP systems deliver sustainable, on-site production of ox-
[email protected] idizers and DNA modification without harmful by-products.

Leadership Designing safe and efficient methods for industrial and commercial water
Ron Barnes treatment, Prozone has manufactured and supplied over a million purifica-
Founder and CEO tion systems throughout the world for point-of-use drinking water, cistern
Cherie Brook and well water systems, aquatics systems, plant, fruit, and vegetable pro-
cessing systems, fisheries, hatcheries, cooling towers, recreational water,
President waste and sewage water treatment.

20 Through its research, Prozone continues to innovate oxidation systems tech-
nology development for International organizations such as United Nations,
NASA, Universities, Corporations and the Departments of Agriculture, De-
fense and the Interior.

Key Technologies:

Prozone Water Products specializes in small to medium sized ozone and
hydroxyl producing and contacting hardware, and has a patent portfolio con-
sisting of ~35 US patents and international patents pending in the following
key areas:
• Ozone Generation using Hybrid Cold Plasma Germicidal VUV – Designed to
harness the VUV spectrum of 185nm photochemical production of ozone and
254nm germicidal DNA modification.
• Ozone and UV-C Advanced Oxidation Processing (AOP) – Photochemical
method in which photons in the UV spectrum convert ozone in the presence
of water to Hydroxyl Radicals in a process known as Advanced Oxidation Pro-
cess. This process allows the conversion of ambient ozone into hydroxyls,
thus eliminating ozone off-gassing.
• Oxygen Fed Corona Discharge Air Cooled Ceramic Flat Plate Ozone Generators
• Contacting Systems using Bypass Dynamic Venturi Injectors and Serpen-
tine Counter-Flow Structures

Testing:

Prozone’s studies and testing focuses on Ozone and Advanced Oxidation
Processes as a means of purifying water; as a biocide for Biofilms; and the
destruction and inactivation of harmful microbes including viruses, bacte-
ria, molds and toxic chemicals. Elimination of Legionella, Cryptosporidium
(“Crypto”), E-coli, Pseudomonas, Staphylococcus, MRSA, C-Diff and other
pathogens found in hospitals, cruise ships, recreational facilities, and reha-
bilitation facilities is a high priority. Prozone’s continuous study of the effi-
cacy of Ozone and AOP technologies on the destruction and remediation of
biofilms in water supply lines in cooling towers, closed loop bodies of water
and throughout buildings are critical to the protection of human health.

These studies are being examined to produce sustainable, on-site products
that will ensure the safe and efficient processing of vegetables, fruit, meat
and preparation of food, storage, and preservation. Capitalizing on the ad-
vantages of ozone and AOP as a principal method in plant hygiene, Prozone’s
systems increase plant health and inhibit inherent issues of mold, fungus,
bacteria, and coliform through the oxidation and DNA modification processes.

www.serinatherapeutics.com Serina Therapeutics, Inc. is a privately-held pharmaceutical
company that is advancing novel therapeutics for Parkinson’s
256.327.0566 disease, restless leg syndrome, cancer, inflammation and pain
[email protected] using its proprietary, patented polymer technology. The company
[email protected] has created new pharmaceutical candidates using polyoxazoline
(POZ) – a safe, water-soluble polymer to which we can attach
Leadership a variety of small molecules, proteins, peptides and DNA. The
Randall Moreadith, M.D., Ph.D. attachment of these molecules to POZ typically confers a unique
pharmacokinetic profile that is markedly different from the
President and Chief Executive Officer parent compound. This profile may confer advantages in terms of
safety and efficacy. In general, molecules attached to POZ stay in
Patricia Sinatra the body for a much longer period of time – and can be precisely
tuned to achieve the desired therapeutic profile.
Senior Vice President of Business
Development Serina Therapeutics has partnered its technology with two of
the top ten pharmaceutical companies worldwide, and is actively
Tacey Viegas, Ph.D. seeking new partnerships. In addition to its partnerships, Serina
Therapeutics holds the global exclusive license to metal-catalyzed
Chief Operating Officer “click chemistry” for the development of POZ-therapeutics.

Mike Bentley, Ph.D. Key Technology

Chief Scientific Officer Novel polymer drug delivery platform based on polyoxazoline - POZ.

Milton Harris, Ph.D. Trials/Testing

Chairman Serina Therapeutics has advanced its first proprietary
compound, SER-214, into clinical trials in patients with
Parkinson’s disease (PD). SER-214 is a once-per-week
injectable that provides continuous drug delivery of a
potent dopamine agonist known as rotigotine. Continuous
dopaminergic stimulation has been a long-sought clinical
strategy in patients with PD for decades, and SER-214 is
unique in this mode of action. SER-214 should obviate the
phasic peak and trough of many oral drugs used to treat
PD – thus preventing “wearing off” and onset of dyskinesia.
The Phase Ia trial was initiated in early 2016 with plans to
complete the study during 2016. For more information please
visit https://clinicaltrials.gov/show/NCT02579473.

21

www.transomic.com Our Mission

256.327.9510 At transOMIC technologies we believe deeply in the power of
[email protected] science and technology to advance the understanding of biological
systems to ultimately improve the quality of life. Our company
Leadership provides innovative tools and strategies for life science research
Blake Simmons to help unravel genetic complexity and understand disease
development. This mission, coupled with a good understanding of
Chief Executive Officer the tools that life science researchers need, drives our focus to
be a research partner, delivering technologies in a cost-effective
Rusla du Breuil and technically supported manner to enable discovery across the
genome. We have one of the largest offerings of gene content to
Chief Technology Officer enable scientists, academic and commercial, to perform gene
knockdown, gene knockout and over-expression studies. These
22 types of studies produce insights into gene function understanding
of disease and possibilities for therapies.

Current Products

Genes for all species: We offer DNA based clones representing
genes from human, mouse, rat, bovine, zebrafish and Xenopus
species allowing scientists to express them in cells and determine
their biological function.

New generation shRNA tools for RNA interference (RNAi): New-
generation RNAi libraries target human, mouse and rat genomes
providing potent, specific and 100% guaranteed gene knockdown.
Innovative RNAi product formats from transOMIC allow scientists to
target hundreds to thousands of genes in parallel greatly reducing
the cost and labor involved with large scale screening studies.
These reagents were developed by eminent cancer researcher
Gregory Hannon at Cold Spring Harbor Laboratory and exclusively
licensed to transOMIC technologies.

transEDIT CRISPR-Cas9 reagents for gene editing: Lentiviral
expression systems provide powerful tools for genome editing,
offering optimized gRNA designs cloned into a choice of expression
vectors and formats for engineering specific gene knock-outs or
knock-ins. Constitutive or inducible Cas9 expression, and a variety
of gRNA and Cas9 vector configurations allow for optimal gene
editing in more biologically relevant cells.

Testing and Laboratory Work

We conduct precise and thorough laboratory testing that
produces high quality data. We do this by implementing
technical procedures and policies that produce reliable
test results.

Microbiology Testing and Analysis

Antimicrobial Efficacy Testing

Biofilm Testing

Extraction of high-quality genomic material

Customized testing protocols

Consultation for Scientific Endeavors

We have a proven track record of scientific consultation
for various clients.

Providing a path-forward for product development

Research Study Design

Data Review and Reporting

Scientific Assessment of various products and technologies

Preparation and Review of scientific documents including grants.

Research and Analysis

You’ll get precise and objective reporting of our findings
that will provide not only an accessible summary of the
data, but a professional analysis and recommendations
relevant to the purpose of the study by award-winning,
experienced scientists.

Our lead scientists have over 30 years of experience in
research and lab operations.

www.trideum.com/page/biosciences

(256) 704-6100

Leadership
Van Sullivan

President

Mina Izadjoo, Ph.D.

Chief Science Officer

23

www.volatileanalysis.com Volatile Analysis Corporation (VAC) is a privately held
company that specializes in volatile chemical utilization,
(256) 486-3531 detection, measurement, and olfaction. Small, volatile
[email protected] (propensity to exist as gas) chemicals are responsible for
all aromas/odors, and quite important in biological and
Leadership industrial applications.
Katherine Bazemore
Research and Development
President & Chief Executive Officer
VAC is a research and development company that focuses
Matthew Shirley on volatile chemical applications. Opportunities are
numerous and include:
Chief Operating Officer
metabolomics (disease diagnosis via trace level volatile
Russell Bazemore, PhD chemical biomarkers present in the breath, perspiration,
urine of humans and animals)
Senoir Vice President of Research & Development
genetic modification impact on the volatile chemical
Chris Christianson, PhD profiles of plants and animals

Senior Vice President, Analytical Services chemical communication (identification and measurement
of chemicals utilized for biological system communication
24 for example pheromones)

olfaction and aroma activity

Hardware and methods for concentrating and identifying
volatile chemicals and their olfaction properties are
also active research areas. Patent-pending technology
includes devices that enhance chemical detection.

Technology

VAC is an analytical problem-solving and consulting
company specializing in the detection, identification,
and measurement of trace level and ultra-trace level
chemicals responsible for odor and aroma. An expert
staff utilizes combinations of analytical chemistry and
sensory analysis to develop strategies for completely
solving or mitigating costly odor problems perceived by
consumers as indicative of tainted, potentially dangerous,
or just unacceptably poor quality products.

VAC works with industries where aroma/odor is important.
Examples include paper and packaging, pharmaceutical,
food and beverage, cosmetic, apparel, manufacturing
(light and heavy), and automotive. The analytical/sensory
division provides deployable aroma/odor analysis and
panel training. Sensory trained staff review industrial
processes and coordinate odor remediation efforts.
Analytical services specializes in quantification of trace
level and ultra-trace level (ng/g or parts per trillion and
lower) chemicals responsible for odor and aroma.

ADDITIONAL COMPANIES AT HUDSONALPHA

Alimetrix is a molecular diagnostic company whose mission is to provide clinicians
with actionable diagnostic information. With unique disease insight, coupled with
proprietary technologies, Alimetrix is able to provide exceptionally accurate test results
in a timely manner. Being armed with finely detailed and accurate information allows
clinicians to gain a clear understanding of the therapeutic needs of the patient. As part
of our clinician partnership we seek to provide best-in-class information, helping to
facilitate better patient outcomes and actively reduce patient suffering.

Concero Scientific’s mission is safeguarding the warfighter and the homeland
from biothreats by accelerating prevention, response and control solutions for
infectious diseases and bioagents through research, development and integration
of cutting-edge life science discoveries.

Envision Genomics is a comprehensive genomic medicine enabler for Children’s
Hospitals committed to improving the quality & reducing the cost of healthcare by
unlocking the genomic sequence for more effective patient care. Envision offers clinical
implementation, clinical grade sequencing, informatics, and precision medicine care
delivery training enabling physicians to practice true precision medicine.

The Jackson Conference Center is located on the HundsonAlpha Biotech
Campus, adjacent to the HudsonAlpha Institute for Biotechnology. The 22,000
square foot conference center, with its flexible meeting space, can host meetings
and conferences for up to 800 guests. The center boasts state of the art audio
visual equipment and an IT support staff that ensures everything runs smoothly.
Experience personalized and efficient service offered by Jackson Center’s hospitality
minded staff. Enjoy fresh, energizing meals prepared by the in house culinary team.

Jackson Center makes it easy to get down to business with no distractions.

MIRA Pharmaceuticals Kymanox is a premier technical products and project management company. We are
experts in providing our clients in the Biotech, Pharma, Device, and Nano industries
with engineering, scientific, regulatory, and process operations support. We help bring
products from bench to patient.

MIRA Pharmaceuticals is a specialty pharmaceutical company that offers a
broad product line of generic liquid and semi-solid prescription drugs. MIRA aspires
to develop and deliver time saving, high quality products sold at a fair price for uses
in the market of generic liquid and semi-solid prescription drugs. The founders
of MIRA believe that the opportunities created by the marketplace, coupled with
the company founder’s extensive experience in the development and marketing of
products in this sector, will serve as a solid foundation for the company and will be
an engine for future growth.

Molecular Logic has developed a suite of technologies and algorithms that, for the first time,
allow unbiased and accurate detection and management of biological populations. These
tools are routinely applied with high impact in the real estate, hospitality, sports, healthcare,
food safety and wastewater management fields.

The Smith Family Clinic for Genomic Medicine has been established to use
whole genome sequencing to diagnose rare, undiagnosed and misdiagnosed
disease. Patients will be seen by a clinical geneticist who will evaluate
symptoms, or patient phenotype, and determine whether whole genome
sequencing is an appropriate test. The data from the genomic sequence is
then interpreted clinically to identify variants, or changes in the DNA, linked
to disease.
Sulfilatec, Inc. is a preclinical-stage biotechnology company aiming to
transform clinical outcomes in dialysis. The company is developing novel
treatments tailored to the unique biochemical profile of dialysis patients in
order to reduce the elevated morbidity and mortality rates associated with
dialysis treatments.
Synvivo,LLC was founded in 2014 as a spin-out from CFD Research Corporation
(CFDRC) to commercialize with the Synvivo family of cell-based assays. Synvivo,
whose name is derived from synthetic in vivo, is a disruptive technology with
a goal to revolutionize drug discovery and precision medicine by providing the
most realistic and dynamic in vitro platform for cellular behavior and drug
response. The two high-tech domains of microfluidics and bioengineering
have enabled Synvivo scientists to analyze and visualize how drugs behave
in real-time offering a true breakthrough in drug development. Even more
importantly, Synvivo is at the forefront of truly personalized, precision medicine
with its technology’s ability to show, in real-time, how a patient will respond to
different drugs or combination therapies.

Thermo Fisher Scientific Inc. is the world leader in serving science, with
50,000 employees in 50 countries. Our mission is to enable our customers to
make the world healthier, cleaner and safer. We help our customers accelerate
life sciences research, solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Our four premier brands – Life
Technologies, Thermo Scientific, Fisher Scientific and Unity Lab Services – offer
an unmatched combination of innovative technologies, purchasing convenience
and comprehensive support.

∞ Ubiquity Ubiquity Genomics provides tools for targeted DNA sequencing. The company’s
Ub Genomics proprietary technology allows researchers to focus genetic and epigenetic analyses
on large regions of the genome at a fraction of the cost of other commercially
available approaches. Ubiquity Genomics offers customized sequencing services,
as well as pre-made targeting kits. The first pre-made kit is Complete MHC, which
enables scientists to sequence the entire MHC locus, a region of great importance
to immunological disease research. Ubiquity also offers kits for the enrichment
of human DNA from contaminated sources, such as saliva. These kits will also
deplete human DNA when the research is focused on the microbiome.

26

“HudsonAlpha gives us an
unparalleled opportunity to work

in a world-class facility where
we can learn and grow with other

entrepreneurs, educators and
basic scientists. The collaborative

environment at HudsonAlpha
has facilitated our growth.”

– Marshall Schreeder, Jr.

Conversant Bio

Next door to discovery - with space, talent and bandwidth to grow.

To learn more about the business advantages of HudsonAlpha and locating your bioscience
company in Huntsville, Alabama, visit hudsonalpha.org/innovate.

601 Genome Way, Huntsville AL 35806 | T: 256.327.9591 | www.hudsonalpha.org